Boston won't see as many BIO attendees this time around; Charity targets stem cell pathway to mend MS damage;

 @FierceBiotech: After death, some stem cells remain alive for days. More | Follow @FierceBiotech

 @RyanMFierce: Human Genome Sciences sets deadline of July 16 for acquisition offers, but not sure how that motivates non-GSK buyers. More | Follow @RyanMFierce

> The BIO convention is expected to draw more than 15,000 people to Boston next week, less than the more than 22,000 who attended the meeting in the hub 5 years ago. Organizers blame the economy for the lower attendance this year. Article

> Bay State officials aim to make use of the BIO conference vehicle to drive further growth in the state's biotech sector. Report

> The Myelin Repair Foundation has gone the stem cell route in a pioneering Phase I trial for treating multiple sclerosis. Release

Pharma News

 @FiercePharma: NICE tells Roche Zelboraf is too expensive. More | Follow @FiercePharma

> Feds nail Internet pharmacy operator for fake drugs. News

> HGS sets deadline for bids: Come and get it! Story

> Drugmakers line up for tsunami of diabetes. More

Medical Device News

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey  | Follow @FierceMedDev

> U.K. regulators cracking down on sale of fake devices. More

> Will the device tax cost lives? Story

> FDA investigates Fresenius over kidney dialysis controversy. Article

> GAO: Orthopedic implantable device admission rates soar. More

And Finally… Viacyte, a San Diego biotech researching cell therapy for diabetes, has named Dr. Paul Laikind its president and CEO. Item

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.